Disclosed are hydrogel compositions comprising both polysaccharide-based and polyzwitterionic components, methods of making the compositions, and methods of using the compositions for various clinical and biomedical applications.

The hyaluronic acid filler according to the present invention exhibits improved high viscoelastic flow characteristics, and has advantages of monophasic hyaluronic acid fillers and biphasic hyaluronic acid fillers together, and therefore it maintains the shape while having low moving possibility when injecting into skin, and thus it is excellent when used for improving wrinkles, augmentation of soft tissues such as cheeks, breast, nose, lips and hips, etc., and correcting contours, and the duration time in the human body is increased and side effects are small, even if a small amount of crosslinking agent is used during the preparation process.

Intravesical devices are provided that are wholly deployable within the bladder of a patient in need of treatment and are well tolerated by the patient. The device may include an elastic body having a retention shape having (i) dimensions that provide intravesical mobility and that prevent voiding of the medical device through the urethra, and (ii) dimensions, buoyancy, or both, that exclude the medical device from entering the orifices of the ureters. The elastic body may exert a maximum acting force less than 1N when compressed to a shape with a maximum dimension in any dimension of 3 cm. The device may include a drug for controlled release within the bladder, for treatment of the bladder or a regional tissue. Methods of treatment are also provided that include selecting a patient in need of treatment in the bladder where tolerability of the treatment is a primary concern.

Intravesical devices are provided that are wholly deployable within the bladder of a patient in need of treatment and are well tolerated by the patient. The device may include an elastic body having a retention shape having (i) dimensions that provide intravesical mobility and that prevent voiding of the medical device through the urethra, and (ii) dimensions, buoyancy, or both, that exclude the medical device from entering the orifices of the ureters. The elastic body may exert a maximum acting force less than 1N when compressed to a shape with a maximum dimension in any dimension of 3 cm. The device may include a drug for controlled release within the bladder, for treatment of the bladder or a regional tissue. Methods of treatment are also provided that include selecting a patient in need of treatment in the bladder where tolerability of the treatment is a primary concern.

In some embodiments, the present invention provides methods for making resorbable ear tubes including the steps of providing a silk fibroin solution, and forming a silk ear tube from the silk fibroin solution, wherein the silk ear tube is less than 2 mm in length and has an outer diameter of less than 1.5 mm, and wherein the silk ear tube is resorbable. In some embodiments, the present invention also provides methods for treating otitis media including the step of introducing a silk ear tube into the ear canal of a subject, wherein the silk ear tube is less than 2 mm in length and has an outer diameter of less than 1.5 mm, and wherein the silk ear tube is resorbed by the subject.

The present invention provides a printed scaffold mat comprising a plurality of fused fibers comprising a first polymer; a coating comprising a second polymer, wherein the coating coats at least a portion of the surface of the plurality of fused fibers; and at least one pharmaceutical compound dispersed within the coating.

A prosthetic venous valve having a conical shaped base valve member and a biomaterial delivery construct. The base valve member includes a plurality of fluid flow modulating means that open and allow antegrade blood to be transmitted out of the valve member when the valve member receives antegrade blood therein, and close and prevent retrograde blood from flowing into the valve member. The biomaterial delivery construct is adapted to receive and position the base valve member therein, and be disposed proximate a luminal wall of a venous vessel.

A soft tissue filler composition including a cross-linked hyaluronic acid and a benzyl alcohol. The benzyl alcohol can be present at a concentration between about 0.1% and about 2.0% by weight of the composition.

Hemostatic devices for promoting blood clotting can include a substrate (e.g., gauze, textile, sponge, sponge matrix, one or more fibers, etc.), a hemostatic material disposed thereon such as kaolin clay, and a binder material such as crosslinked calcium alginate with a high guluronate monomer molar percentage disposed on the substrate to substantially retain the hemostatic material material. When the device is used to treat a bleeding wound, at least a portion of the clay material comes into contact with blood to accelerate clotting. Moreover, when exposed to blood, the binder has low solubility and retains a majority of the clay material on the gauze. A bandage that can be applied to a bleeding wound to promote blood clotting includes a flexible substrate and a gauze substrate mounted thereon.

The present technology relates to depots for the treatment of postoperative pain via sustained, controlled release of a therapeutic agent. In some embodiments, the depot may comprise a therapeutic region comprising an analgesic, and a control region comprising a bioresorbable polymer and a releasing agent mixed with the polymer. The releasing agent may be configured to dissolve when the depot is placed in vivo to form diffusion openings in the control region. The depot may be configured to be implanted at a treatment site in vivo and, while implanted, release the therapeutic agent at the treatment site for no less than 3 days.